Table 5.
The percentage of each sex1 that tested positive2 for IgM and IgG antibody production in the FMG in ovo vaccination treatment3 at 14, 21, and 28 d of age.
| IgM antibody production (% Serum plate agglutination positive) |
|||
|---|---|---|---|
| Age | Total # positive | % Male positive | % Female positive |
| 14 | 17 | 58.8 | 41.2 |
| 21 | 19 | 73.7 | 26.3 |
| 28 | 20 | 50.0 | 50.0 |
| IgG antibody production (% ELISA positive) |
|||
| Age | Total # positive | % Male positive | % Female positive |
| 14 | 0 | 0.0 | 0 |
| 21 | 1 | 0 | 100 |
| 28 | 7 | 42.9 | 57.1 |
1
Sex was determined by necropsy of the deceased birds and evaluation of the internal reproductive organs.
2
Blood samples collected from the birds were tested for IgM antibodies against MG by serum plate agglutination (SPA) testing and were tested for IgG antibodies against MG by ELISA testing.
3
Chickens were vaccinated with Poulvac Myco F (Zoetis) live attenuated strain F Mycoplasma gallisepticum (FMG) vaccine at 18 d of incubation with a 10−6 dilution of the vaccine in a 50 µL volume. The vaccine was resuspended and diluted in Poulvac Marek's diluent (Zoetis, Exton, PA).